May 6, 2009
The Melanoma Research Foundation, the largest private foundation devoted to the prevention and treatment of melanoma, will honor CommereNet’s own Dr. Jay M. Tenenbaum for his ongoing support. The “Legends for a Cure” gala will be held Thursday, May 14, 2009 at the San Francisco Film Centre in San Francisco. More details about the event and how to donate can be found at www.melanoma.org.
February 25, 2009
According to the Cambridge Health Institute (CHI), “the need for a more precise, predictive approach to medicine has never been greater, as we face two fundamental crises in the biotech and pharmaceutical industries. Healthcare costs are spiraling out of control in the face of near epidemics in diabetes and Alzheimer’s disease, an aging population, and soaring costs of new technology. Moreover, the pharmaceutical industry struggles as increasing costs, patient expirations, and the demise of the blockbuster model puts a premium on innovation and efficiency.
For 16 years, CHI has tracked the growth, challenges, and opportunities in this space; and on February 25 – 27, 2009, it will host the 16th International Molecular Medicine Tri-Conference in San Francisco, California.
CommerceNet’s own Dr. Jay M. Tenenbaum will give a plenary keynote on February 25 from 8:55 – 9:40am that focuses on “Therapy Development in a Network World.”
To hear the presentation
December 15, 2008
CommerceNet will be hosting its annual holiday party–complete with its traditional chocolate fountain–on Monday, December 15. Attendance is by invite only.
Want to attend? Contact Keren Wasserman for more information. All RSVPs are due by December 1.
November 7, 2008
CommerceNet Chairman and Founder Dr. Jay M. Tenenbaum attended the National Cancer Institute (NCI) Translational Science Meeting, November 7 – 9, 2008, at the Grand Hyatt Hotel in Washington, D.C.
This by-invitation-only event is designed to identify opportunities for accelerating the conversion of basic science discovery to the point of early state clinical trials using a poster discussion format.
October 22, 2008
Jeff Shrager, CTO at CollabRx, a CommerceNet portfolio company, participated in a panel titled “Pharma and Health 2.0” at this year’s Health 2.0 Conference in San Francisco. During the session, Dr. Shrager demonstrated how the CollabRx e-science platform connects researchers to one another and to a network of scientific services.
Health 2.0: User-Generated Healthcare 2008
The San Francisco Marriott
October 22 – 23, 2008
Breakout Session D (October 23, 2008)
Pharma and Health 2.0
Read full agenda
Register for the event
October 7, 2008
The PRISM Forum has an international membership of senior life science informaticians drawn from a number of biopharmaceutical organizations. The Forum meets twice a year, once in Europe and once in the USA, to exchange precompetitive information and to consider the application of emerging IT technologies within the biopharmaceutical research process.
Marty Tenenbaum, chairman and founder of CommerceNet and chairman and chief scientist of CollabRx (a CommerceNet Portfolio company), gave the keynote address at the PRISM special interest group on open innovation. His presentation focused on the structural problems in the existing drug development process and how open innovation and Health Commons can minimize them–making it affordable to develop treatments for rare and orphan diseases.
Imagine a virtual marketplace or ecosystem where participants share data, knowledge, materials, and services to accelerate research. This Health Commons is a bold vision whose aim is no less than to change the processes, economics, and culture of translating basic research into drugs.
25+ million patients and their families suffer from over 6,000 orphan diseases that are currently uneconomical to address. The time is ripe for a radically different approach that leverages collaboration and the Internet to enable small teams of researchers to develop new therapies in a cost-effective manner and get them to patients quickly.
Virtual biotechs, using innovative research and clinical and business strategies, will exploit the Commons to slash the time and costs associated with drug development. As a result, a small group of patients with a rare disease can fund the development of new therapy in time to save their own lives. In the age of genomic sub-typing and personalized medicine–where every disease is potentially an orphan disease–the implications are far-reaching.
October 3, 2008
Jonathan Jacoby, COO at CollabRx, a CommerceNet portfolio company, participated in a panel discussion on “Organizational Structure, Leadership, and Financial Models” at an Institute of Medicine workshop titled “Venture Philanthropy Strategies Used by Patient Organizations to Support Translational Research.” The workshop took place on October 3, 2008, in Irvine, CA.
- Explored several elements of how a program should be organized to ensure appropriate expertise and leadership is available
- Examined a variety of organizational and financial models that may provide optimal support for translational research programs
September 10, 2008
On September 10, 2008, The BIG Health Consortium was launched to demonstrate the reality of personalized medicine. An exceptional group of almost 30 senior leaders from academe, government, advocacy, policy, and commerce convened for the kickoff. Marty Tenenbaum, chairman and founder of CommerceNet and chairman and chief scientist of CollabRx (a CommerceNet portfolio company) was among the participants.
Learn more about The Big Health Consortium event
September 7, 2008
Rachna Dhamija and Allan M. Schiffman–CEO and CTO at Usable Security Systems, a CommerceNet portfolio company–are demonstrating UsableLogin, the company’s new product, at DEMOfall08 in San Diego.
September 6, 2008
CommerceNet Fellow Lisa Dusseault attended DjangoCon September 6 – 7, 2008, in Mountain View, California.
As the first international Django conference, DjangoCon aims to bring the community together for a wide range of sessions, panels, lightning talks, and showcases featuring Django usage within various businesses.